In an 85-year-old female with diabetes and chronic kidney disease stage 3a, with total cholesterol 208 mg/dL and LDL‑C 129 mg/dL, which statin—rosuvastatin or atorvastatin—is preferred?

Atorvastatin is the preferred choice for this 85-year-old female with diabetes and CKD stage 3a

For an elderly patient with diabetes and CKD stage 3a, atorvastatin should be prescribed over rosuvastatin due to better-established safety data in older adults with renal impairment and lower risk of proteinuria.

Guideline-Based Rationale

The 2018 ACC/AHA cholesterol guidelines clearly establish that CKD (eGFR <60 mL/min/1.73 m²) is a risk-enhancing factor for atherosclerotic cardiovascular disease 1. For this patient with diabetes and CKD stage 3a, statin therapy is strongly indicated—the guidelines recommend moderate-intensity statin therapy or moderate-intensity statin combined with ezetimibe 1.

Key Considerations for Statin Selection in This Patient

Age-Related Factors (85 years old)

The geriatrics literature emphasizes that statin recommendations in adults ≥85 years should account for comorbidities, frailty, and life expectancy 2. While guidelines don't explicitly favor one statin over another in this age group, they stress extra vigilance for adverse effects and consideration of lower starting doses 2.

Renal Safety Profile

Critical distinction: Rosuvastatin carries specific FDA warnings about proteinuria and hematuria, particularly at higher doses 3. The FDA label explicitly states: "dipstick-positive proteinuria and microscopic hematuria were observed among rosuvastatin treated patients...more frequent in patients taking rosuvastatin 40 mg" and recommends "a dose reduction for patients on rosuvastatin therapy with unexplained persistent proteinuria" 3.

In contrast, atorvastatin's FDA label indicates that "renal disease has no influence on the plasma concentrations or LDL-C reduction of atorvastatin" 4, making it more predictable in CKD.

Recent real-world evidence from Chinese patients with diabetes and CKD found that rosuvastatin was associated with a dose-dependent higher risk of new-onset albuminuria compared to atorvastatin 5. This is particularly concerning for your patient who already has CKD stage 3a.

Cardiovascular Efficacy

While rosuvastatin may achieve slightly greater LDL-C reductions milligram-per-milligram 6, 7, both statins effectively reduce cardiovascular events in patients with diabetes and CKD 5, 8. A 2025 Korean study found comparable cardiovascular effectiveness between the two statins 8, though rosuvastatin showed a modestly higher risk of peripheral arterial disease in adults ≥65 years 8.

Practical Prescribing Algorithm

Start with atorvastatin 10-20 mg daily:

• 10 mg if concerned about tolerability given age and multiple comorbidities
• 20 mg if prioritizing more aggressive LDL-C lowering (moderate-intensity)

Monitor at 4-12 weeks:

• Lipid panel (target LDL-C reduction of 30-50% for moderate-intensity)
• Creatinine/eGFR
• Urinalysis for proteinuria
• AST/ALT
• Assess for muscle symptoms

Titration strategy:

• If LDL-C goal not met: increase to atorvastatin 40 mg or add ezetimibe 10 mg
• If proteinuria worsens: continue atorvastatin (less likely culprit than rosuvastatin)
• If muscle symptoms: reduce dose or consider alternate-day dosing

Critical Pitfalls to Avoid

1. Don't use rosuvastatin 40 mg in CKD: The FDA specifically warns about increased proteinuria risk at this dose 3, and your patient already has compromised renal function

2. Don't ignore baseline urinalysis: Check for proteinuria before starting therapy to establish baseline, as both diabetes and CKD can cause albuminuria independent of statin therapy

3. Don't assume dose equivalence: Rosuvastatin 5 mg ≈ atorvastatin 10 mg in LDL-lowering, but side effect profiles differ significantly in CKD 3, 4

4. Don't overlook drug interactions: At 85 years, polypharmacy is common. Atorvastatin is metabolized by CYP3A4 4, so avoid strong inhibitors (clarithromycin, itraconazole, cyclosporine)

Dosing Specifics for Your Patient

Given her LDL-C of 129 mg/dL and total cholesterol of 208 mg/dL:

• Atorvastatin 20 mg daily (moderate-intensity) would be expected to reduce LDL-C by approximately 40-50%, bringing her to ~65-77 mg/dL
• This achieves the <100 mg/dL target for high-risk patients and approaches the optional <70 mg/dL target for very high-risk patients 1

Atorvastatin offers the optimal balance of efficacy, renal safety, and tolerability in this elderly patient with diabetes and CKD stage 3a, with lower risk of worsening proteinuria compared to rosuvastatin.